melanocortin receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-06 and is reviewed periodically as new material appears.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
== R == RCM – Rapid Communications in Mass Spectrometry REIMS – Rapid evaporative ionization mass spectrometry REMPI – Resonance enhanced multiphoton ionization RGA – Residual gas analyzer RI – Resonance ionization
==== Actions ==== RO5203648 binds to the mouse, rat, cynomolgus monkey, and human TAAR1 all with high affinity (Ki = 0.5–6.8 nM). It is a potent partial agonist in all species (EC50Tooltip half-maximal effective concentration = 4.0 to 31 nM), with an efficacy of 48 to 73% relative to the endogenous TAAR1 agonists β-phenethylamine and tyramine and the TAAR1 full agonist RO5166017. RO5203648 is highly selective for the TAAR1, showing ≥130-fold selectivity for the mouse TAAR1 over 149 other targets.
== Legal status == Sweden's public health agency suggested classifying 4-fluorobutyrylfentanyl as hazardous substance on August 18, 2014. In October 2015, 4-fluorobutyrylfentanyl became a controlled substance in China. 4-Fluorobutyrfentanyl is a Schedule I controlled drug in the USA since 1. February 2018.
Sources: en.wikipedia.org
== Release == Portal was first released as part of The Orange Box for Windows and Xbox 360 on October 10, 2007, and for the PlayStation 3 on December 11, 2007. In addition to Portal, The Orange Box includes Half-Life 2 and its two add-on episodes, as well as Team Fortress 2. Portal's inclusion within The Orange Box was considered an experiment by Valve; having no idea of the success of Portal, the bundle provided it a "safety net" via means of these other games. Portal was kept to a modest length in case the game did not go over well with players. The game was released as a standalone retail product on April 9, 2008, with the Windows version also available as a download through Steam. In January 2008, Valve released a special demo titled Portal: The First Slice, free to any Steam user using Nvidia graphics hardware, as part of a collaboration between the two companies. The demo comes packaged with Half-Life 2: Deathmatch, Peggle Extreme, and Half-Life 2: Lost Coast. The demo includes test chambers 00 to 10 (eleven in total). Valve has since made the demo available to all Steam users. Portal is the first Valve-developed game to be added to the OS X-compatible list of games available on the launch of the Steam client for Mac on May 12, 2010, supporting Steam Play, in which buying the game on Macintosh or Windows computer makes it playable on both. As part of the promotion, Portal was offered as a free game for any Steam user during the two weeks following the Mac client's launch. Within the first week of this offer, over 1.5 million copies were downloaded through Steam.
The most commonly used synthetic membrane devices (modules) are flat sheets/plates, spiral wounds, and hollow fibers. Flat membranes used in filtration and separation processes can be enhanced with surface patterning, where microscopic structures are introduced to improve performance. These patterns increase surface area, optimize water flow, and reduce fouling, leading to higher permeability and longer membrane lifespan. Research has shown that such modifications can significantly enhance efficiency in water purification, energy applications, and industrial separations. Flat plates are usually constructed as circular thin flat membrane surfaces to be used in dead-end geometry modules. Spiral wounds are constructed from similar flat membranes but in the form of a "pocket" containing two membrane sheets separated by a highly porous support plate. Several such pockets are then wound around a tube to create a tangential flow geometry and to reduce membrane fouling. Hollow fiber modules consist of an assembly of self-supporting fibers with dense skin separation layers, and a more open matrix helping to withstand pressure gradients and maintain structural integrity. The hollow fiber modules can contain up to 10,000 fibers ranging from 200 to 2500 μm in diameter; The main advantage of hollow fiber modules is the very large surface area within an enclosed volume, increasing the efficiency of the separation process.
1946 in Cairo), historian, academic, scholar, author of over fifteen books, essayist, Emeritus Professor of Comparative European History at Queen Mary, University of London . George Sassoon (30 October 1936 – 8 March 2006), British scientist, electronic engineer, linguist, translator and science fiction author of Iraqi Jewish Mizrahi Jewish origin; author of The Manna-Machine (1978) and The Kabbalah Decoded (1978). Siegfried Sassoon, writer and WW1 poet, of Iraqi Jewish Mizrahi Jewish origin. Charles Saatchi (Arabic: تشارلز ساعتجي; born 9 June 1943); author of numerous books, periodicals, journals and monographs on art and culture, Mizrahi Jewish Iraqi-Jewish British businessman and co-founder, with brother Maurice, of advertising agency Saatchi & Saatchi, the world's largest advertising agency; later formed a new agency called M&C Saatchi; also known for his art collection and for owning Saatchi Gallery, and for sponsorship of the Young British Artists (YBAs), including Damien Hirst and Tracey Emin.Successful campaigns included Silk Cut's advertisements and those for Conservative Party's 1979 general election victory – led by Margaret Thatcher through the slogan "Labour Isn't Working". Other clients included British Airways. In the Sunday Times Rich List 2009 ranking of the wealthiest people in the UK, was grouped with brother Maurice, with estimated fortune of £120 million.
Sources: en.wikipedia.org
==== Blood stains ==== There are several reddish stains on the shroud suggesting blood. McCrone (see painting hypothesis) showed that these contain iron oxide, and theorized that its presence was likely due to simple pigment materials used in medieval times. While the forensic doctor Pierluigi Baima Bollone initially claimed in 1983 to have identified type AB human blood along with traces of serum, aloes, and myrrh, this conclusion was later challenged by researchers like Alan Adler and more recently Kelly Kearse, who noted that early testing methods could not definitively confirm ancient human blood due to degradation and potential contamination. Skeptics cite forensic blood tests whose results dispute the authenticity of the Shroud, and point to the possibility that the blood could belong to a person who handled the shroud, and that the apparent blood flows on the shroud are unrealistically neat. As of 2025, it has not been scientifically demonstrated that the blood is of human, or even primate, origin.
The wrapping of meat or other foodstuffs into dough can be traced back to the Classical Greek or Roman eras. Early versions of the roll with pork as a filling proved popular in London during the Napoleonic Wars and it became identified as an English dish. On 20 September 1809, the Bury and Norwich Post mentions T. Ling, aged 75, (an industrious vendor of saloop, buns, and sausage rolls). The Times first mentions the food item in 1864 when William Johnstone, "wholesale pork pie manufacturer and sausage roll maker", was fined £15 (£1,300 in 2021), under the Nuisances Removal Act (Amendment) Act 1863, for having on his premises a large quantity of meat unsound, unwholesome and unfit for food. In 1894, a theft case provided further insights into the Victorian sausage roll production whereby the accused apprentice was taught to soak brown bread in red ochre, salt, and pepper to give the appearance of beef sausage for the filling.
=== Analogues and derivatives === Analogues of 2C-B include 2C-I, 2C-C, DOB, 4C-B, 2C-B-FLY, and 25B-NBOMe, among others. DOB and 4C-B are α-alkyl derivatives of 2C-B, specifically the amphetamine (α-methyl) and phenylisobutylamine (α-ethyl) derivatives, respectively. β-Substituted derivatives of 2C-B such as BOB (β-methoxy-2C-B), BOH-2C-B (β-hydroxy-2C-B), βk-2C-B (β-keto-2C-B), and β-methyl-2C-B (BMB) have been described. βk-2C-B shows dramatically reduced potency and efficacy as a serotonin 5-HT2A receptor agonist compared to 2C-B. A variety of N-substituted derivatives of 2C-B have been tested, including N-methyl-2C-B, N,N-dimethyl-2C-B, N-ethyl-2C-B, and N-benzyl-2C-B. Most simple alkyl derivatives were considerably less potent than 2C-B, with N-ethyl-2C-B for instance having a 40 times lower affinity for the serotonin 5-HT2A receptor. The N-benzyl derivative however was found to have higher affinity than 2C-B itself, with N-(4-bromobenzyl)-2C-B binding even more tightly. This initial research did not include functional assays of activity, but later led to the development of potent substituted N-benzyl derivatives such as 25B-NBOMe, and 25B-NBOH. Another N-substituted derivative, 2C-B-AN, is an N-benzylphenethylamine-like prodrug of 2C-B. 2C-DB (6-bromo-2C-B) is a ring-substituted derivative of 2C-B. TWEETIO derivatives of 2C-B, in which one or both of the methoxy groups of 2C-B are extended to ethoxy groups, exist as well, such as 2CB-2-EtO.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.